Standard Cosentyx Dosing Schedule
Cosentyx (secukinumab) is typically dosed every 4 weeks after the initial loading doses for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. For adults with plaque psoriasis, treatment starts with 300 mg (two 150 mg subcutaneous injections) at weeks 0, 1, 2, 3, then 300 mg every 4 weeks thereafter. Psoriatic arthritis and ankylosing spondylitis follow 150 mg (or 300 mg for psoriasis) weekly for the first month, then every 4 weeks.[1][2]
When Are Dose Adjustments Made?
Adjustments occur based on clinical response, not on a fixed interval. Guidelines recommend evaluating efficacy at 12-16 weeks after starting therapy. If inadequate response (e.g., less than 75% improvement in psoriasis area severity index), physicians may increase the dose from 150 mg to 300 mg every 4 weeks, switch treatments, or discontinue. No routine interval exists between adjustments; changes depend on patient monitoring, often every 3 months during maintenance.[1][3]
Adjustments for Other Conditions
- Hidradenitis suppurativa: Starts at 300 mg weekly for 4 weeks, then every 4 weeks; assess response at week 16 and adjust if needed.
- Non-radiographic axial spondyloarthritis: Same as ankylosing spondylitis; evaluate at 16 weeks.
- Pediatric psoriasis (6+ years, ≥50 kg): 300 mg loading, then every 4 weeks; lighter children get 75-150 mg with similar assessment timing.[2][4]
Factors Influencing Adjustment Timing
Weight, disease severity, and comorbidities affect starting doses and adjustment needs. For example, patients under 90 kg may start at 150 mg. Infections or loss of response prompt earlier checks, but standard follow-up aligns with 4-week dosing intervals for convenience. No patent data specifies dosing patents; Cosentyx exclusivity runs through 2023 in the US, with biosimilars pending.[1][5]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: American Academy of Dermatology Guidelines on Psoriasis
[4]: European Medicines Agency Cosentyx Summary
[5]: DrugPatentWatch.com - Cosentyx Patents